Related Experiment Video

Updated: Feb 7, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.5K

[Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment]

A G Obrezan1, N V Kulikov1

  • 1Federal State Budgetary Educational Institution of Higher Education "Saint-Petersburg State University".

Kardiologiia
|August 8, 2018
PubMed

Insights

This study examines diabetes mellitus (DM) and chronic heart failure (CHF) risk factors and mortality. It highlights SGLT2 inhibitors and lifestyle changes as effective treatments for patients with both conditions.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Diabetes mellitus (DM) significantly impacts chronic heart failure (CHF) prevalence and progression.
  • Understanding the interplay between DM and CHF is crucial for effective patient management.

Purpose of the Study:

  • To analyze the prevalence and risk factors of CHF in diabetic patients.
  • To evaluate mortality rates in patients with and without DM based on ejection fraction.
  • To review current and emerging therapeutic strategies for DM and CHF.

Main Methods:

  • Review of scientific studies on DM and CHF prevalence and risk factors.
  • Analysis of mortality data stratified by DM status and ejection fraction.
  • Characterization of pharmacological treatments for CHF, with a focus on diabetic patients.

Main Results:

  • Identified key risk factors for CHF in DM patients including hyperglycemia, obesity, age, and diabetic complications.
  • Demonstrated the efficacy of Sodium-glucose co-transporter 2 (SGLT2) inhibitors, particularly empagliflozin, in managing CHF in diabetic individuals.
  • Highlighted the benefits of lifestyle modifications and metformin in obese patients with or without DM and CHF.

Conclusions:

  • SGLT2 inhibitors represent a promising therapeutic avenue for patients with comorbid DM and CHF.
  • Lifestyle modifications and medications like metformin offer additional benefits, especially in obese patients.
  • Integrated management strategies are essential for improving outcomes in patients with DM and CHF.

Keywords:
diabetes mellitusheart failurepathogenesistreatment

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure06:46

Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure

Published on: December 22, 2023

1.2K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348